Interleukin-6 (IL-6)

Overview

Interleukin-6 (IL-6) is a small secreted signaling protein — a pleiotropic cytokine of roughly 21–28 kDa, depending on glycosylation — produced by a wide range of cell types including T cells, B cells, monocytes and macrophages, fibroblasts, endothelial cells, and adipocytes. It is one of the principal mediators of the acute phase response, driving hepatic production of C-reactive protein (CRP) and fibrinogen, and it also contributes to B-cell differentiation into antibody-secreting plasma cells, T-helper cell polarization (notably toward IL-17A–producing Th17 cells), hematopoiesis, and metabolic regulation. Its many historical names — B-cell stimulatory factor 2, hybridoma growth factor, interferon beta-2 — reflect the independent lines of research that converged on a single protein.

IL-6 signals through a receptor complex comprising the ligand-binding IL-6 receptor and the shared signal-transducing subunit gp130, engaging both classic signaling on cells expressing membrane-bound IL-6R and trans-signaling via soluble IL-6R, which extends responsiveness to cells that lack the receptor and is generally associated with pro-inflammatory effects. Receptor engagement activates the JAK/STAT cascade, principally JAK2 and STAT3, alongside the Ras–MAPK and PI3K–Akt pathways. IL-6 transcription is itself induced by upstream inflammatory signaling, including Toll-like receptor 4 activation by lipopolysaccharide, NF-κB, and NLRP3 inflammasome–associated responses, placing it in a tightly coupled network with tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-18, and CXCL8. Because circulating IL-6 concentrations track systemic inflammation, the protein is widely used as a biomarker — in sepsis, traumatic brain injury, cardiovascular risk stratification, and chronic inflammatory and metabolic disease — and as a component of multi-analyte diagnostic panels. Sustained IL-6 signaling is implicated in rheumatoid arthritis and other autoimmune conditions, atherosclerosis, obesity-associated insulin resistance and type 2 diabetes, cytokine release syndromes including severe COVID-19, and tumor progression through STAT3-driven survival and angiogenic programs involving VEGFA. These roles have made the pathway a validated drug target: antibodies against IL-6 and its receptor, such as tocilizumab and siltuximab, are approved therapies, and JAK inhibitors block signaling downstream. IL-6 is also a recurrent hub node in network pharmacology analyses of anti-inflammatory natural products, including polyphenols and flavonoids such as quercetin, baicalein, and naringenin.

Recent Publications Summary

Recent publications continued to position IL-6 as a central inflammatory biomarker and mechanistic node across diverse disease settings. In a prospective study of severe traumatic brain injury, IL-6 was among the key mediators consistently elevated in both plasma and cerebrospinal fluid during the first week after injury, alongside IL-8 and IL-10, highlighting a dynamic early inflammatory response in blood and CSF 42360398Jun. In tuberculosis patients evaluated for myocardial infarction, IL-6 was incorporated into a four-biomarker diagnostic panel with hs-cTnI, myoglobin, and CK-MB, where the combined model showed strong diagnostic performance and the assay achieved very low analytical detection limits for IL-6 42314097Jun. A DNA-engineered immunosensing platform likewise demonstrated ultrasensitive IL-6 detection with a low limit of detection and broad dynamic range, supporting its use for clinical biomarker measurement 41655520Feb.

Several studies examined IL-6 in association with inflammatory disease activity and treatment response. In dogs with thoracolumbar intervertebral disc disease receiving acupuncture, plasma IL-6 showed limited but measurable treatment-related change, with a significant pre-post difference only in the classical needle acupuncture group during the acute phase 42371222Jun. In monozygotic twins discordant for pain-related temporomandibular disorder, painful twins had significant within-pair differences in IL-6 and the IL-6/IL-10 ratio, consistent with a pro-inflammatory peripheral profile linked to pain severity and mechanical sensitivity 42132960May. In children with type 1 diabetes, serum IL-6 was evaluated together with oncostatin M for relationships with glycemic indices, reflecting ongoing interest in IL-6 as a marker of inflammatory dysregulation in metabolic disease 41917697Apr. A prospective study in adults with recently diagnosed type 2 diabetes also assessed circulating IL-6 as a prognostic biomarker for diabetic retinopathy progression 41794136Mar.

IL-6 also appeared repeatedly in network pharmacology, molecular docking, and experimental studies of natural products and herbal formulations. quercetin from Cyathulae Radix was identified as a principal active component in an osteoporosis-focused network analysis in which IL-6 was among the core targets, and quercetin improved oxidative injury and osteogenic differentiation in pre-osteoblasts 42474720Jul. Scutellaria baicalensis was studied in a rat model of polycystic ovary syndrome, where IL-6 was one of the central targets implicated in modulation of the NF-κB and Toll-like receptor signaling pathways 42294648Jun. Shenling Baizhu Powder was similarly linked to IL6 in ulcerative colitis with spleen deficiency and dampness stagnation, and Astragalus membranaceus fermentation studies identified IL6 as a core target in diabetic nephropathy 42089391May42009593Apr. Wine-processed Radix Paeoniae Rubra showed docking affinity to IL-6, and Convolvulus oxyphyllus extracts suppressed IL6 expression in anti-inflammatory assays 42000152Apr42128884May. In osteoarthritis, artificial mitochondria reduced inflammatory pathways including IL6 while restoring cellular energy metabolism 41816316Mar.

Beyond these mechanistic and diagnostic studies, IL-6 was also reported in broader inflammatory and cardiovascular contexts. A large pooled cohort analysis evaluated circulating IL-6 as a prognostic marker for multiple cardiovascular and mortality outcomes, including myocardial infarction, stroke, heart failure, and all-cause mortality 42201287May. In severe COVID-19, IL-6 was among the biomarkers associated with coagulopathy in a single-center observational cohort 42065184May. In peripartum cardiomyopathy, IL-6 was examined histopathologically alongside tenascin-C as a potential prognostic factor 41905945Mar. Additional studies assessed IL-6 in cervical cancer progression across weight categories, in inflammatory biomarker profiling for diabetic retinopathy, and in systemic cytokine alterations in periodontitis, underscoring its continued use as a readout of inflammatory burden across clinical research 42049436Apr41794136Mar41910651Mar.

What Changes, What Holds

1. IL-6 remains a broadly useful inflammatory readout, with stronger support for multiplex and ultrasensitive measurement
METHOD Recent work does not alter IL-6 biology, but it strengthens its practical role as a measurable biomarker across acute injury and cardiovascular diagnostics. The main change is technical: newer assays and combined panels improve detection and clinical discrimination, reinforcing the Overview’s point that circulating IL-6 tracks systemic inflammation. 42360398Jun42314097Jun

2. IL-6 continues to mark inflammatory burden, but its disease-specific meaning remains context dependent
REINFORCES These studies mostly sharpen the existing picture that IL-6 rises with inflammatory activity and may track treatment response or prognosis in metabolic and pain-related disorders. They do not displace the Overview’s account; instead, they add more examples where IL-6 behaves as a nonspecific pro-inflammatory signal, while also showing that effect sizes and clinical utility can be modest or unsettled. 42371222Jun42132960May

3. IL-6 is increasingly treated as a core target in natural-product and pathway analyses, but that adds examples rather than a new role
REINFORCES The new work extends the long-standing network-pharmacology pattern in which IL-6 appears as a central inflammatory node downstream of NF-κB and related pathways. Nothing here contradicts the Overview’s mechanistic framing; the main implication is that IL-6 remains a frequent convergence point in preclinical anti-inflammatory screening, though these target lists do not by themselves establish clinical relevance. 42474720Jul42294648Jun

4. IL-6 is gaining support as a prognostic marker across cardiovascular and infectious complications, but its predictive value is still broad rather than specific
REINFORCES These findings fit the established view of IL-6 as a systemic inflammation biomarker linked to adverse outcomes in cardiovascular disease and severe infection. They broaden the range of settings in which IL-6 is associated with risk, but they do not change the underlying biology or prove that IL-6 adds unique prognostic information beyond other inflammatory signals. 42201287May42065184May

Overview update candidates: ultrasensitive and multiplex IL-6 measurement; broader prognostic use as a cardiovascular and inflammatory biomarker.